Skip to search formSkip to main contentSkip to account menu

Cobimetinib

An orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

5 relations
Cobimetinib 20 MG Oral Tablet [Cotellic]Kinase Inhibitors [MoA]NCIt Antineoplastic Agent Terminology

Narrower (1)

Cotellic

Broader (1)

GDC-0973

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study.
10023Background: The phase 3 IMspire150 study (NCT02908672) demonstrated improved progression-free survival with first-line… 
2020
2020
Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study.
122Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts… 
2018
2018
Abstract P5-21-01: Cobimetinib combined with paclitaxel as first-line treatment for patients with advanced triple-negative breast cancer (COLET study): Primary analysis of cohort I
Chemotherapy is the mainstay of treatment for triple-negative breast cancer (TNBC), but taxane resistance remains problematic… 
2017
2017
Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.
3057Background: A, an anti–programmed death-ligand 1 (PD-L1) monoclonal antibody, inhibits PD-L1/programmed death-1 (PD-1) and PD… 
2017
2017
Abstract CT107: A Phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors
Background: Dysregulation of the MAPK pathway, initiated by mutations in the RAS or BRAF oncogenes or through upstream growth… 
Review
2016
Review
2016
The Systemic Management of Advanced Melanoma in 2016
Melanoma is a common type of skin cancer with a high propensity to metastasize. Tyrosine kinase inhibitors targeting the mitogen… 
2016
2016
Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF-mutated melanoma patients (pts) with poor and favorable prognosis in the coBRIM phase III study.
9530Background: In coBRIM, C+V significantly improved PFS and OS versus placebo (P)+V in pts with BRAFV600-mutated advanced… 
2015
2015
Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma.
9020 Background: BRIM7 formed the basis for development of the VEM + COBI regimen, which, in a randomized phase III trial… 
2015
2015
Use of Transgenic Mouse Models to Understand the Oral Disposition and Drug-Drug Interaction Potential of Cobimetinib, a MEK Inhibitor
Data from the clinical absolute bioavailability (F) study with cobimetinib suggested that F was lower than predicted based on its… 
2015
2015
Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B).
TPS9088 Background: Significant advances in the management of melanoma have improved the prognosis and overall survival of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)